VTVT
vTv Therapeutics Inc.35.14
+1.38+4.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
138.38MP/E (TTM)
-Basic EPS (TTM)
-3.30Dividend Yield
0%Recent Filings
8-K
Cadisegliatin Phase 3 update
vTv Therapeutics posted an updated March 2026 investor presentation detailing cadisegliatin, its Phase 3 oral adjunctive therapy for type 1 diabetes with FDA Breakthrough Designation. CATT1 trial enrollment wraps in 3Q 2026, building on Phase 2 data showing HbA1c cuts and fewer hypoglycemic events. No approved oral T1D options exist. Forward-looking statements carry risks.
8-K
vTv reports 2025 results, $20M milestone
vTv Therapeutics reported full-year 2025 net loss of $27.0 million, with cash surging to $88.9 million from $36.7 million, fueled by $80 million financing. February 2026 brought $20.0 million upfront from Newsoara for HPP737 global rights, plus up to $115 million milestones and royalties. Cash funds past CATT1 Phase 3 enrollment, now due Q3 2026. Balance sheet strengthened.
10-K
FY2025 10-K: no financials
vTv Therapeutics' 10-K for FY2025 ended December 31, 2025 lacks financial statements, revealing no revenue, profitability, or quarterly metrics. No Q4 results or trends disclosed. Recent license amendments with Newsoara expanded territory worldwide and added milestones like $20M payment upon effectiveness, yet no cash flow or EPS data provided. Liquidity posture undisclosed. No annual guidance given. Clinical trial delays risk stalling momentum.
8-K
Cadisegliatin Phase 3 update
vTv Therapeutics posted an updated February 2026 investor presentation detailing cadisegliatin, its Phase 3 oral adjunctive therapy for type 1 diabetes with FDA Breakthrough Designation. Topline CATT1 data, targeting hypoglycemia reduction and HbA1c improvement, is expected in 2H 2026. Phase 2 showed good tolerability. Cadisegliatin advances alone.
8-K
Global HPP737 license expansion
vTv Therapeutics LLC signed the Second Amendment to its license agreement with Newsoara Biopharma on January 30, 2026, expanding Newsoara's rights to the PDE4 inhibitor HPP737 worldwide upon a $20 million upfront payment. Newsoara must pay up to $50 million in development milestones, $65 million in sales milestones, and mid-single-digit royalties. Cash bolsters vTv's runway. Milestone risks remain.
ALT
Altimmune, Inc.
5.03-0.25
APLT
Applied Therapeutics, Inc.
0.12+0.00
DMAC
DiaMedica Therapeutics Inc.
8.76+0.09
IVA
Inventiva S.A. - American Depos
4.66+0.18
MTVA
MetaVia Inc.
8.14-0.17
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
VKTX
Viking Therapeutics, Inc.
35.72-0.43
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
ZVRA
Zevra Therapeutics, Inc.
8.12-0.05
ZVSA
ZyVersa Therapeutics, Inc.
0.13-0.00